Robert S, the abstract you post is a review (check the end), not an original research, full of hypothesis and the work of others (most of the time the reviewer is one of the top researchers in the subject, or a young fellow starting a career). This is important to start reading about a subject, but it will be better to have the full article ( I will try, but it takes time to find it, sometimes weeks).
It deals mainly on traditional antibiotics and their role in the release of endotoxin.
General idea: some antibiotics kill the bacteria and release the endotoxins, others do not. The author is not sure what is better, if endotoxins are not release then some defense mechanisms are not started, but if they are a lot of inflammation comes by.
BPI goes further, it helps in the killing, it helps regulate the immune defense response, and it regulates it with little if any inflammatory damage, plus other positive actions, like decreasing problems with intravascular coagulation and/or bleeding disorders.
A very superior model, with very good basic sciences and animal experiments supporting it, and mounting evidence from several phase I, and II human subjects studies. To wait for the phase III results is the clue. The article post by Robert K does give you some answer to this question, is a review of some of the experience on BPI actions and pharmacokinetics, indeed a very good choice as a reply.
The stock is very low price, maybe extremely cheap.
If one believe in all the previous evidence then one is a holder and of course a nervous one waiting to make it or break it, like me.
If one does not believe, I suspect like you, is better to wait on the sidelines, see the price go up slowly toward the end of the year and when the results comes out lose some of the upside, and pick it less cheap, but still cheap, or even wait a little bit after the initial hoopla and pick it after the profit taking. Not a bad strategy either.
Best luck and jump at the right time.
cacaito |
